Cytek Biosciences, Inc. reports recurring developments in cell analysis instruments, reagents, services, and financial performance. The company uses patented Full Spectrum Profiling™ (FSP®) technology to analyze fluorescence signals in flow cytometry and related cell analysis workflows.
News about Cytek Biosciences commonly covers earnings releases, revenue trends, recurring service and reagent revenue, instrument placements, product platforms such as Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, Cytek Aurora™ Evo, Cytek Orion™, ESP™ detection technology, and Amnis® and Guava® products, as well as investor conference participation and business outlook updates.
Cytek Biosciences has introduced the Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ and Cytek Northern Lights™ systems. This upgrade allows researchers to detect subcellular particles, such as extracellular vesicles (EVs), with superior sensitivity and resolution. The global EV market is projected to grow significantly, from $227.5 million in 2023 to $1.3 billion by 2028, at a CAGR of 42.2%. This advancement positions Cytek as a leader in the small particle research market. The ESP Detection Option enhances the study of viruses, bacteria, and nanoparticles, offering unprecedented light scatter sensitivity and enabling more accurate measurement and characterization of small particles.
Cytek Biosciences reported strong financial results for the first quarter of 2024, with total revenue reaching $44.9 million, a 21% increase from the previous year. The company's organic revenue saw a significant 11% growth, driven by the acquisition of product lines from Luminex Cytek also expanded its operations by opening a new facility in China and received approval for a TBNK panel. Despite a decrease in gross profit margin, the company remains focused on sustainable growth and profitability. Cytek reaffirmed its revenue guidance for 2024, expecting a positive net income for the year.
Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its Full Spectrum Profiling™ (FSP™) technology at CYTO 2024 and AAI’s IMMUNOLOGY2024. The company offers cell analysis solutions for various fields like immunology and oncology. They will conduct educational workshops, tutorials, and exhibit their suite of instruments, reagents, software, and services at these conferences.
Cytek Biosciences, Inc. (Nasdaq: CTKB) will report its first quarter 2024 financial results on May 8, 2024. The management will hold a conference call to discuss the results, business developments, and outlook.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.